Literature DB >> 16732585

Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance.

Mirko Hirschl1, Katharina Hirschl, Matthias Lenz, Reinhold Katzenschlager, Hans-Peter Hutter, Michael Kundi.   

Abstract

OBJECTIVE: To assess the early signs, risk factors, and rate of transition from primary Raynaud's phenomenon (primary RP) to secondary RP.
METHODS: A clinical sample of 307 consecutive patients with RP was included in a prospective followup study. After an initial screening, 244 patients were classified as having primary RP, of whom 236 were followed up for a mean +/- SD of 11.2 +/- 3.9 years. Patients classified according to the screening as having suspected secondary RP underwent an extended screening program annually until transition to secondary RP occurred.
RESULTS: The initial prevalence of secondary RP was 11%. The annual incidence of transition to suspected secondary RP was 2%, and the annual incidence of transition to secondary RP was 1%. Overall, 46 patients were classified as having suspected secondary RP, and 23 of these later were classified as having secondary RP. Older age at onset of RP (hazard ratio 2.59, 95% confidence interval [95% CI] 1.40-4.80), shorter duration of RP at enrollment (hazard ratio 0.87, 95% CI 0.81-0.94), and abnormal findings on thoracic outlet test (hazard ratio 2.69, 95% CI 1.12-6.48) were associated with an increased risk for transition to secondary RP. Compared with patients with suspected secondary RP, those diagnosed as having secondary RP had a higher number and earlier occurrence of pathologic findings. Furthermore, antinuclear antibodies at a titer of > or = 1:320 and positive findings in specific serologic subsets were associated with a significantly increased risk for developing a connective tissue disease.
CONCLUSION: Patients diagnosed initially as having primary RP may actually comprise 1 of 3 groups: those with idiopathic RP, those with a rather benign disease course, and those with a more severe course of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732585     DOI: 10.1002/art.21912

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  24 in total

Review 1.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

Review 2.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

Review 3.  Raynaud's phenomenon (primary).

Authors:  Janet Pope
Journal:  BMJ Clin Evid       Date:  2013-10-10

4.  Vascular acrosyndromes in young adult population. Definition of clinical symptoms and connections to joint hypermobility.

Authors:  Periklis Vounotrypidis; Athina Pyrpasopoulou; Grigorios T Sakellariou; Dimitrios Zisopoulos; Nikoleta Kefala; Dimitrios I Oikonomou; Constantinos Stefanis; Spyros Aslanidis; Charalambos Bermperidis; Periklis Pappas
Journal:  Clin Rheumatol       Date:  2019-06-08       Impact factor: 2.980

5.  Disease modification in systemic sclerosis. Do integrated approaches offer new challenges?

Authors:  M Cutolo
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

6.  Perfusion Scintigraphy for the Evaluation of Patients with Raynaud's Phenomenon.

Authors:  Ari Chong
Journal:  Nucl Med Mol Imaging       Date:  2020-10-22

7.  Late appearance and exacerbation of primary Raynaud's phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients.

Authors:  Slavica Pavlov-Dolijanovic; Nemanja S Damjanov; Nada Z Vujasinovic Stupar; Goran L Radunovic; Roksanda M Stojanovic; Dragan Babic
Journal:  Rheumatol Int       Date:  2012-07-22       Impact factor: 2.631

Review 8.  Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.

Authors:  Pia Moinzadeh; Svetlana I Nihtyanova; Kevin Howell; Voon H Ong; Christopher P Denton
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 9.  Raynaud's phenomenon (primary).

Authors:  Janet Elizabeth Pope
Journal:  BMJ Clin Evid       Date:  2008-12-16

Review 10.  The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

Authors:  Lesley Ann Saketkoo; Jeanette H Magnus; Mittie K Doyle
Journal:  Am J Med Sci       Date:  2014-01       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.